Tonix Pharmaceuticals Holding Corp. (TNXP)
8.91
-0.32
(-3.47%)
USD |
NASDAQ |
Oct 02, 16:00
8.85
-0.06
(-0.67%)
After-Hours: 20:00
Tonix Pharmaceuticals Net Income (Quarterly) : -40.55M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -40.55M |
| March 31, 2026 | -40.19M |
| December 31, 2025 | -46.91M |
| September 30, 2025 | -32.01M |
| June 30, 2025 | -28.27M |
| March 31, 2025 | -16.83M |
| December 31, 2024 | -22.11M |
| September 30, 2024 | -14.21M |
| June 30, 2024 | -78.78M |
| March 31, 2024 | -14.94M |
| December 31, 2023 | -27.32M |
| September 30, 2023 | -27.98M |
| June 30, 2023 | -28.36M |
| March 31, 2023 | -33.00M |
| December 31, 2022 | -31.68M |
| September 30, 2022 | -28.98M |
| June 30, 2022 | -23.14M |
| March 31, 2022 | -26.42M |
| December 31, 2021 | -29.55M |
| September 30, 2021 | -18.53M |
| June 30, 2021 | -23.55M |
| March 31, 2021 | -20.65M |
| December 31, 2020 | -17.02M |
| September 30, 2020 | -11.99M |
| June 30, 2020 | -14.18M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.273M |
| December 31, 2019 | -8.707M |
| September 30, 2019 | -7.838M |
| June 30, 2019 | -5.84M |
| March 31, 2019 | -6.233M |
| December 31, 2018 | -7.588M |
| September 30, 2018 | -5.479M |
| June 30, 2018 | -6.087M |
| March 31, 2018 | -6.935M |
| December 31, 2017 | -5.493M |
| September 30, 2017 | -5.786M |
| June 30, 2017 | -4.78M |
| March 31, 2017 | -5.064M |
| December 31, 2016 | -7.482M |
| September 30, 2016 | -7.578M |
| June 30, 2016 | -9.806M |
| March 31, 2016 | -13.98M |
| December 31, 2015 | -13.36M |
| September 30, 2015 | -13.25M |
| June 30, 2015 | -11.76M |
| March 31, 2015 | -9.681M |
| December 31, 2014 | -8.989M |
| September 30, 2014 | -7.419M |
| June 30, 2014 | -6.044M |
| March 31, 2014 | -5.164M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -6.012M |
| Nektar Therapeutics | -40.62M |
| Heron Therapeutics, Inc. | -5.489M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 13.54M |
| Total Expenses (Quarterly) | 54.10M |
| EPS Diluted (Quarterly) | -2.438 |
| Enterprise Value | -25.34M |
| Gross Profit Margin (Quarterly) | 90.24% |
| Profit Margin (Quarterly) | -299.4% |
| Earnings Yield | -145.2% |
| Normalized Earnings Yield | -145.15 |